8-K
filed May 28, 2026, 4:15 PM ET
ticker KPTI
CIK 0001503802
other material
confidence high
sentiment neutral
materiality 0.55
Karyopharm shareholders approve equity plan amendments; board approves milestone-based PSU awards for executives
Karyopharm Therapeutics Inc.
- Shareholders approved 3M share increase under 2022 Equity Incentive Plan and 1.4M under ESPP at May 21 annual meeting.
- Directors Barry E. Greene and Christy J. Oliger elected as Class I directors for three-year terms.
- Board approved retention program granting PSUs vesting on clinical milestones; CEO Richard Paulson awarded 343,000 PSUs per award.
- Named executives (CMO, CFO, CDO) each received 130,000-150,000 PSUs per award; total 3,838,380 PSUs granted to all eligible employees.
- Board adopted further amendment to increase authorized shares by 950,000, subject to stockholder approval by May 31, 2027.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Karyopharm Therapeutics Inc. shareholders approved Amendment to the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan to increase shares available by 1,400,000 at the 2026-05-21 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-05-21
Exact text from the filing
3. The Company’s stockholders approved an amendment to the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan, as amended, to increase the number of shares of the Company’s common stock available for issuance thereunder by 1,400,000 shares. The results of the stockholders’ vote with respect to such approval were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 11,221,920 203,702 5,063 5,410,881
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Karyopharm Therapeutics Inc. shareholders approved Election of Barry E. Greene and Christy J. Oliger as Class I directors at the 2026-05-21 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-21
Exact text from the filing
1. The Company’s stockholders elected Barry E. Greene and Christy J. Oliger as Class I directors, each to serve on the Board for a three-year term until the 2029 annual meeting of stockholders and until his or her resignation or removal or until his or her successor is duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class I directors were as follows: Votes For Votes Withheld Broker Non-Votes Barry E. Greene 8,961,538 2,469,147 5,410,881 Christy J. Oliger 10,601,387 829,298 5,410,881
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Karyopharm Therapeutics Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-21 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-21
Exact text from the filing
4. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The results of the stockholders’ vote with respect to such approval were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 10,025,198 1,388,274 17,213 5,410,881
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Karyopharm Therapeutics Inc. shareholders approved Amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan to increase shares available by 3,000,000 at the 2026-05-21 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-05-21
Exact text from the filing
2. The Company’s stockholders approved an amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended, to increase the number of shares of the Company’s common stock available for issuance there under by 3,000,000 shares. The results of the stockholders’ vote with respect to such approval were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 10,474,681 953,411 2,593 5,410,881
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Karyopharm Therapeutics Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-21 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-21
Exact text from the filing
5. The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows: Votes For Votes Against Votes Abstaining 16,695,588 86,550 59,428
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.